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Finally, the pace of innovation in psoriasis therapy is accelerating.
For 50 years, only four systematic therapies (Methotrexate,
PUVA, oral retinoids, and cyclosporine) enjoyed substantial use
(Greaves and Weinstein, 1995). Although often e¡ective, each of
these therapies has associated risks. In the next few years, a large
number of new systemic agents for psoriasis are likely to become
available. Although di¡ering in mechanism, many of these new
treatments alter immunity and some should be considered im-
munosuppressive (Granstein, 2001; Gri⁄ths, 2002). As a result,
increased risks of infection and certain cancers as documented
for cyclosporine in this issue of the JID and elsewhere for cyclo-
sporine and other potentially immunosuppressive psoriasis thera-
pies must be considered in determining the long-term safety of
these agents (Paul, this issue JID; Marcil and Stern, 2001; Margo-
lis et al, 2001).
In contrast to the codi¢ed study methodologies required for
initial drug approval, uniform regulatory requirements to assess
adverse events that are likely to only emerge with prolonged use
are generally lacking. Rather, regulatory agencies and companies
typically negotiate postmarketing safety requirements (if any) at
the time a new agent is approved. The study by Paul et al pub-
lished this month highlights a number of important issues con-
cerning the evaluation of long-term safety for systematic
therapies for psoriasis and other chronic dermatologic diseases.
Among these issues are: (1) When is a cohort study likely to ade-
quately quantify long-term relative and absolute risks? (2) What
long-term safety issues can be adequately addressed from the
study of other populations using the same drug long-term (i.e.,
those without psoriasis)? (3) How does the organization, ¢nan-
cing and control of safety studies a¡ect the likelihood that a study
will provide a robust safety evaluation? (4) How can we insure the
timeliness and balanced presentation of safety data for multiple
competing drugs with a common therapeutic indication? These
issues are important to practitioners and patients, as well as phar-
maceutical and biotechnology companies who contemplate the
development of systemic medications for psoriasis and other
chronic diseases.
The appropriateness, feasibility, utility, and design of a cohort
study meant to establish the safety of a treatment of a chronic
disease such as psoriasis depends on a number of factors, includ-
ing: (1) the hypothesis to be tested; (2) power desired; (3) the
availability of appropriate controls or comparator data; (4) the an-
ticipated duration of use; and (5) latency between exposure and
the detection of an associated adverse event. These factors, rather
than commercial considerations, should govern study design.
Advance hypotheses provide strong guidance in study design.
In the case of the new immunomodulatory agents for psoriasis,
the long-term safety issues are generally similar to those for cy-
closporine and have been the subject of debate for more than a
decade (Stern, 1989). They include malignancy, particularly squa-
mous cell cancer of the skin, lymphoproliferative disorders, infec-
tion, immunologic reaction to the agent itself, and autoimmune
disease. For all endpoints except skin cancer, if available, data
from demographically comparable populations treated with com-
parable dose and for similar duration for other indications should
provide information that is highly likely to be applicable to pa-
tients with psoriasis.
After controlling for exposure to potential carcinogens, the
risk of nonmelanoma skin cancer and melanoma among patients
with psoriasis is comparable to genetically similar persons living
in the same geographic areas (Stern et al, 1985). However, as a re-
sult of exposure to a variety of potentially carcinogenic therapies,
patients with psoriasis who are candidates for systemic immuno-
suppressive therapy are likely to be at higher risk of skin cancers,
particularly squamous cell carcinoma (SCC) (Stern and Laird,
1994). Further, interactions between prior therapies and subse-
quent immunosuppressive treatment may put some individuals
at extremely high risk.We know those with high levels of expo-
sure to natural sunlight are at particularly high risk of SCC fol-
lowing long-term immunosuppression. For example, the risk of
squamous cell carcinomas among Australian transplant recipients
is far higher than transplant patients in Europe (Ramsay et al,
2002). Long-term therapeutic ultraviolet-B exposure among psor-
iasis patients may have a similar e¡ect, but this has not been sys-
temically assessed. Paul con¢rms that prior exposure to PUVA is
a risk factor for SCC among patients who subsequently utilize
cyclosporine, but he did not examine the relation of level of dose
of PUVA to this risk. An earlier study demonstrates that exposure
to at least 200 PUVA treatments and subsequently use of cyclo-
sporine was associated with extremely high SCC risk, nearly an
average of nearly one SCC per year per person, an incidence
equalled only by Australian transplants (Marcil and Stern, 2001;
Ramsay et al, 2002). Less exposure to PUVA did not have a sig-
ni¢cant e¡ect on SCC risk during cyclosporine therapy.
From studies in both psoriasis and the general population, we
know that the risk of squamous cell cancer increases with the
duration and dose of therapy of immunosuppressive therapy. The
possible persistence of increased risk after immunosuppressive
therapy is stopped is particularly important for younger patients
using immunosuppressive therapy, but this issue has not been sys-
tematically assessed. In organ transplant patients, skin cancer risk
is lower during the ¢rst two years of immunosuppressive therapy
than subsequently (Ramsay et al, 2002). Therefore, the power of a
study to detect important increases in risk is a function of its
duration, the completeness of follow-up as well as the size and
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characteristics of the study population. Particularly important de-
terminants of the expected incidence of SCC in a study popula-
tion are age, skin type, geographic residence, total exposure to
other potential carcinogens and the interval since these exposures.
Although complex, robust assessments of skin cancer risk
should be feasible in reasonably sized studies of psoriasis patients,
the relatively low incidence of lymphoreticular malignancies in
the general population makes precise risk assessment of this end
point more di⁄cult in psoriasis studies. In Paul’s study, although
not statistically signi¢cant, the incidence of lymphoma was high-
er in the ‘‘high’’ exposure group, suggesting increased risk with
increased dose. In fact, detection of just one more lymphoma in
this study’s high dose group would have yielded a substantial (8.6
fold) increase in risk that would have been signi¢cant. Further,
the lack of complete follow up raises further questions about the
‘‘lack of signi¢cance’’of the study’s ¢nding concerning lymphoma
in high dose patients. In assessing risk, the conservative assump-
tion is that the incidence of adverse events is higher among those
not followed than those followed.Therefore, it remains unknown
whether substantial increase in the relative risk of lymphoma seen
in other populations occurs at the lower doses of cyclosporine
used in psoriasis (Opelz and Henderson, 1993). Paul’s study does,
however, permit us to exclude a high absolute risk of lymphoma
with substantial con¢dence.
Excluding a high absolute risk of SCC among psoriasis pa-
tients and determining the relation of dose for use on the basis
of Paul’s report is less feasible. Especially useful in determining
risk attributable to a therapy is examining variation in risk
among groups followed for the same interval but who vary sub-
stantially in the level of exposure to the agent under study as well
as other attributes and exposures related to skin cancer risk.
If a study’s ¢ndings are to be robust, possible latency between
exposure and cancer development also requires complete follow-
up for a substantial period (for SCC at least 80% follow-up for 5
years seems a minimum). Because of lower baseline incidence of
SCC in Europe even if all other factors are comparable, a Eur-
opean psoriatic study requires two to ¢ve times the number of
person years of follow-up to have the same power to detect a sig-
ni¢cant increase in risk as a study in the United States. Good data
on dose and duration and not just ‘‘ever used’’ for all relevant ex-
posures both at entry and during follow-up is especially impor-
tant if interactions between multiple therapies are to be
quanti¢ed.
A long-term study with patients enrolled at 277 centers in 11
countries speaking at least 8 di¡erent languages presents a for-
midable challenge. When the determinants of study success are
considered, such a design seems far from ideal. Paul and col-
leagues have done admirably well with a study of this design,
but one might speculate about why the sponsors chose this
design.
The design of company sponsored postmarketing ‘‘safety’’ stu-
dies often appears to be more marketing than science driven (La
Puma et al, 1995). One can understand the temptation to a phar-
maceutical company to mask a seeding study (i.e., a way to get
practitioners comfortable with use of therapy) as a safety study.
Since companies are likely to be the only funding source for
most postmarketing safety studies, motivating companies to resist
this temptation is essential if safety concerns about a drug are
substantial and robust answers are desired. At present, many
forces make it di⁄cult for a company to resist the temptation to
make marketing rather than safety the primary determinant of a
study’s design. Typically, postmarketing safety studies are a result
of ‘‘Phase 4’’ agreements made between regulatory agencies and
companies as a condition of approval. The company that con-
ducts the more rigorous study is likely to have the ¢ndings of this
study, especially if published, used against them by the competi-
tion whose apparent safety advantage might simply re£ect a less
rigorous study. Today, investigators face the choice of doing it the
company’s way or not doing it at all. In times when it is so di⁄-
cult to support clinical research, there is little choice but to do it
the company’s way.
In view of these unfortunate circumstances, accurate quanti¢-
cation of the carcinogenic risk of new immunomodulatory thera-
pies for psoriasis will require change in the ways safety studies are
organized, ¢nanced and conducted. Highly motivated indepen-
dent academic investigators adequately trained to design and con-
duct the long-term safety studies are needed. Of course this will
not be enough. The ground rules and quality standards that gov-
ern long-term safety studies must change and become as rigorous
as those for pre-approval studies.
Only the timely completion of well designed and executed
safety studies can provide the information needed for optimal de-
cision making in treating a chronic disease. Employees of phar-
maceutical companies or contract research organizations, whose
economic well being is dependent on the continued pleasing of
companies (remember Enron and ArthurAnderson, respectively),
should not design or conduct these studies. Clear incentives to
independent investigators to collect robust, accurate and complete
data are needed. These investigators must control the design of
the study, the data, and be free to publish their ¢ndings. The ul-
timate responsibility for insuring the robustness of postmarket-
ing safety studies rests with the regulatory authorities. If there
are su⁄cient long-term safety concerns about a treatment to re-
quire a study, that agency should require that the results of an in-
dependently conducted high quality study be submitted in a
timely manner or the drug’s approval be withdrawn.
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